Skip to main content
Equibles
URGN logo

URGN · UroGen Pharma Ltd. · Metrics

Track URGN — free

Use URGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research URGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$41.15 -3.85 (-8.56%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.20B
Shares
48.88M

URGN metrics

67 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$45.00
Market cap
$2.20B

Price action

20 metrics
Price change (1W)
+1.0%
Price change (30D)
-5.4%
Price change (3M)
+55.5%
Price change (6M)
+125.3%
Price change (YTD)
+87.1%
Price change (1Y)
+104.6%
Trailing year
Price change (5Y)
+166.0%
52-week high
$50.29
52-week low
$16.42
Change from 52-week high
-12.9%
Change from 52-week low
+166.8%
Annualized volatility
65.6%
Annualized volatility (3M)
53.5%
Beta
1.2
RSI (14D)
47.3
Price vs SMA 50
+2.3%
Price vs SMA 200
+54.4%
Avg volume (3M)
816,862
Relative volume
0.9
Average dollar volume
$33.92M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.88M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
11.8×
reciprocal yield 8.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
11.4×
reciprocal yield 8.8%
P / book
—
FCF yield
-7.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
90.8%
Operating margin
-35.3%
Trailing 12 months
Net margin
-51.7%
Gross profit (TTM)
$171.46M
Operating profit (TTM)
−$66.65M
Net income (TTM)
−$97.64M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-84.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.18

Growth

11 metrics
Revenue growth YoY
+199.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$188.73M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.5%
Year over year · more shares
Revenue CAGR (3Y)
+19.5%
Revenue CAGR (5Y)
+56.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-38.7%
Debt / equity
—
Current ratio
3.8
EBITDA (TTM)
−$66.34M
Free cash flow (TTM)
−$159.13M
Quick ratio
3.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$79.44M
Latest balance sheet
Cash & equivalents
$79.13M
Total assets
$252.59M
Total debt
$188.73M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$158.92M
Capital expenditures (TTM)
$218,000
R&D (TTM)
$61.26M
SG&A (TTM)
$176.85M
Stock compensation (TTM)
$16.11M
R&D / revenue
32.5%
Stock compensation / revenue
8.5%

Ownership (13F)

3 metrics
13F filers
191
13F filer change QoQ
+16
Institutional ownership
87.6%

Short interest

3 metrics
Short interest
12.8%
Latest settlement · 6.8 days to cover
Days to cover
6.8d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.71M
Insider-sentiment score
21 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1668243 CUSIP M96088105 13F (30d) 129 filings 129 filers Visit website Investor relations